MoonLake Immunotherapeutics
HealthcareNASDAQ:MLTX · NASDAQ Capital Market
+$0.94 today
Vol 0.74M · Avg 1.00M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-74.7%
avg 41.6%
ROIC
-64.4%
avg -281.7%
ROA
-53.6%
avg -117.4%
Analysis
ROA is currently the strongest return metric at -53.6% versus its period average of -117.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Kristian Reich | Co-Founder & Chief Scientific Officer | $795,472.00 | — | 60 | $520,342.00 | 0.71% |
Jorge Santos da Silva | Co-Founder, Interim Chair of the Board & CEO | $787,308.00 | — | 49 | $2.92M | 3.97% |
Matthias Bodenstedt | Chief Financial Officer | $626,532.00 | — | 38 | $1.17M | 1.59% |
Nicolas Mosimann | General Counsel | — | — | — | — | — |
Tino Anthamatten | Vice President of Marketing, Market Access & Pricing | — | — | — | — | — |
Luciana Marques | Associate Vice-President of HR, People and Culture | — | — | — | — | — |
Wulf Boecher | Chief Medical Officer | — | — | — | — | — |
Oliver Daltrop | Chief Technical Officer | — | — | — | — | — |
Carla Bretes | Director of Investor Relations & External Communications | — | — | — | — | — |
Nuala Brennan | Chief Clinical Development Officer | — | — | — | — | — |
Joana Cortez | Associate Vice-President of Legal & Compliance | — | — | — | — | — |
Roman Akbar-Haase | Chief of Staff to the Executive Board | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$98,808.30
Sells
19
$121.70M
Net Sentiment
$121.60M
Net selling
Most Active
Bodenstedt Matthias
5 transactions
1–10 of 20
Analysis
Insiders reported 1 buys worth $98,808.30 and 19 sells worth $121.70M over the last 12 months. That adds up to net selling of $121.60M. Bodenstedt Matthias was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Erasca, Inc.
NASDAQ:ERAS
$4.37B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.42B
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
$1.19B
Absci Corporation
NASDAQ:ABSI
$1.06B
Ventyx Biosciences, Inc.
VTYX
$1.00B
MeiraGTx Holdings plc
NASDAQ:MGTX
$888.13M
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$862.12M
CytomX Therapeutics, Inc.
NASDAQ:CTMX
$484.08M
REGENXBIO Inc.
NASDAQ:RGNX
$344.31M
Verastem, Inc.
NASDAQ:VSTM
$284.19M
Who manages MLTX?
MoonLake Immunotherapeutics (MLTX) lists 12 active executives. The top listed executive is Nicolas Mosimann, General Counsel.
Are MLTX insiders buying or selling?
Recent insider activity shows net selling of $116.85M.
Explore More
Continue the stock analysis
Jump to another research area for this company.